Key result
Higher serum APOC3 predicts incident CVD in T1DM, while Apoc3 inhibition prevents accelerated atherosclerosis.
Cohort
Answers are grounded in this paper and cite their sources.
Type 1 diabetes mellitus (T1DM) increases the risk of atherosclerotic cardiovascular disease (CVD) in humans by poorly understood mechanisms. Using mouse models of T1DM-accelerated atherosclerosis, we found that relative insulin deficiency rather than hyperglycemia elevated levels of apolipoprotein C3 (APOC3), an apolipoprotein that prevents clearance of triglyceride-rich lipoproteins (TRLs) and their remnants. We then showed that serum APOC3 levels predict incident CVD events in subjects with T1DM in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study. To explore underlying mechanisms, we investigated the impact of Apoc3 antisense oligonucleotides (ASOs) on lipoprotein metabolism and atherosclerosis in a mouse model of T1DM. Apoc3 ASO treatment abolished the increased hepatic Apoc3 expression in diabetic mice - resulting in lower levels of TRLs - without improving glycemic control. APOC3 suppression also prevented arterial accumulation of APOC3-containing lipoprotein particles, macrophage foam cell formation, and the accelerated atherosclerosis in diabetic mice. Our observations demonstrate that relative insulin deficiency increases APOC3 and that this results in elevated levels of TRLs and accelerated atherosclerosis in a mouse model of T1DM. Because serum levels of APOC3 predicted incident CVD events in the CACTI study, inhibiting APOC3 might reduce CVD risk in T1DM patients.
No takes yet. Share an insight, caveat, or question.
Kanter et al. (2019) conducted a cohort in Type 1 diabetes mellitus (T1DM) and atherosclerotic cardiovascular disease. Serum apolipoprotein C3 (APOC3) levels / Apoc3 antisense oligonucleotides (ASOs) was evaluated on Incident cardiovascular disease (CVD) events and accelerated atherosclerosis. Serum APOC3 levels predicted incident CVD events in T1DM patients in the CACTI study, and Apoc3 ASO treatment prevented accelerated atherosclerosis in T1DM mice.
Synapse has enriched 10 related papers. Consider them for comparative context: